Forcyte Biotechnologies
Los Angeles
About Forcyte Biotechnologies
Forcyte Biotechnologies, Inc. was formed to leverage FLECS Technology (originally developed in the Di Carlo Lab @ UCLA) to provide drug-makers and researchers direct access to cellular force generation at the single-cell level – a cellular behavior that was previously inaccessible in an automated way.Forcyte Biotechnologies provide a fundamentally new class of cell-based assays that functionally evaluate single-cell contractility, integrated into standard multi-wellplate vessels – available both as end-to-end services, and as consumables.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Last round: Series Unknown (Jun 2022)
- Website: forcytebio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/forcyte-biotechnologies-1944144 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.